Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Insmed provides update on Iplex launch
July 14th, 2006
Insmed, Inc., (INSM) provided an update on the launch of Iplex (mecasermin rinfabate (rDNA origin) injection) and the company's payer utilization program for the treatment of patients with severe short stature associated with severe primary IGF-I deficiency (Primary IGFD). On May 23, 2006, Insmed announced the Iplex utilization program to approximately 800 national payers as part of its comprehensive launch communications. In a letter to payers, Insmed informed them of the availability and pricing of Iplex. Prominent in the announcement was a statement specifically detailing Insmed's pricing commitment to this market. Insmed proactively created the...
Source: Genomics & Genetics Weekly (2006-07-14)
|
